[HTML] Thyroid Hormone Replacement Therapy in Patients with Various Types of Cancer
A Hercbergs, PJ Davis, HY Lin, KA Keating, SA Mousa - … Therapy and Replacement …, 2019
… hypothyroidism is a common disorder and prescriptions for l -thyroxine (T4)
replacement therapy are among … biologic half-life means that more than once
daily dosing is required for replacement … involved in cell-to-cell and …
replacement therapy are among … biologic half-life means that more than once
daily dosing is required for replacement … involved in cell-to-cell and …
 |  |
[HTML] Effect of Ambroxol chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease
B Charkhand, MH Scantlebury, A Narita, A Zimran… - Molecular Genetics and …, 2019
… Enzyme replacement therapy (ERT), the main stay treatment for Gaucher
disease (GD), is not efficacious for … by Narita et al., Ambroxol in combination
with ERT, may be a promising therapy for patients … activity in Patient 1 was …
disease (GD), is not efficacious for … by Narita et al., Ambroxol in combination
with ERT, may be a promising therapy for patients … activity in Patient 1 was …
| |
Targeted enzyme delivery systems in lysosomal disorders: an innovative form of therapy for mucopolysaccharidosis
A Safary, MA Khiavi, Y Omidi, MA Rafi - Cellular and Molecular Life Sciences, 2019
… Sever form a. Fusion protein to IDS (AGT-182) b. Fusion protein to IDS (JR …
disorders, including gene therapy, cell ther- apy, small molecule therapies,
enzyme replacement therapy (ERT), utilization of … The idea of treating the …
disorders, including gene therapy, cell ther- apy, small molecule therapies,
enzyme replacement therapy (ERT), utilization of … The idea of treating the …
| |
[HTML] Temporal validation of the CT-PIRP prognostic model for mortality and renal replacement therapy initiation in chronic kidney disease patients
D Gibertoni, P Rucci, M Mandreoli, M Corradini… - BMC Nephrology, 2019
… disease, eGFR decline is the main driver of adverse renal outcomes [12],
because it reflects the underlying nephropathy, and patients' adherence and
response to specific therapies. However, the ability of the CT-PIRP model …
because it reflects the underlying nephropathy, and patients' adherence and
response to specific therapies. However, the ability of the CT-PIRP model …
| |
MRNA Delivery For Therapeutic Anti-Her2 Antibody Expression In Vivo
Y Rybakova, PS Kowalski, Y Huang, JT Gonzalez… - Molecular Therapy, 2019
… 18 19 Keywords: mRNA therapeutic, mRNA design, mRNA delivery,
nanoparticles, breast cancer, 20 antibody therapy, Herceptin 21 22 … For
example, in human endostatin the 116 replacement of native SP with Gaussia …
nanoparticles, breast cancer, 20 antibody therapy, Herceptin 21 22 … For
example, in human endostatin the 116 replacement of native SP with Gaussia …
| |
Other Peripheral Neuropathies
B Watterworth, TB Wright - Pain, 2019
… which are most commonly autosomal dominant affecting a myelin protein
gene … Enzyme replacement therapy is a specific therapy which may decrease
progression, but neuropathic pain … treatment has historically been liver …
gene … Enzyme replacement therapy is a specific therapy which may decrease
progression, but neuropathic pain … treatment has historically been liver …
| |
iTRAQ comparison of proteomic profiles of endometrial receptivity
S Pérez-Debén, J Bellver, P Alamá, S Salsano… - Journal of Proteomics, 2019
… a comparison of the endometrial protein profile from women with different
endometrial receptive grade (fertile women, IUD carriers and RIF patients)
during the same period of time (overlapping with the window of implantation) …
endometrial receptive grade (fertile women, IUD carriers and RIF patients)
during the same period of time (overlapping with the window of implantation) …
| |
Osteoporosis and sarcopenia
S Lello, A Capozzi, G Scambia - Maturitas, 2019
… perspective. Furthermore, estrogen can modulate the skeletal muscle protein turnover,
a mechanism through which hormone replacement therapy may reduce degenerative
changes in postmenopausal muscle tissue. In addition …
a mechanism through which hormone replacement therapy may reduce degenerative
changes in postmenopausal muscle tissue. In addition …
| |
[PDF] The challenge of removal of sepsis markers by continuous hemofiltration
PM Honore, D De Bels, R Attou, S Redant, K Kashani - Critical Care, 2019
… Hence, the odyssey continues! Abbreviations CRP: C-reactive protein; CRRT:
Continuous renal replacement therapy; mCRP: Monomeric CRP; MR-proADM:
Mid-regional pro-adrenomodullin; MW: Molecular weight; PCT: Procalcitonin …
Continuous renal replacement therapy; mCRP: Monomeric CRP; MR-proADM:
Mid-regional pro-adrenomodullin; MW: Molecular weight; PCT: Procalcitonin …
| |
[PDF] Encapsulation-free controlled protein release system
M Shoichet, MM PAKULSKA, IE DONAGHUE… - US Patent App. 16/097,916, 2019
… Long term delivery of protein therapeutics is required in numerous chronic
disease or injury treatments, including, for … related macular degeneration;
neurotrophins for axon regeneration following central nervous system injury; …
disease or injury treatments, including, for … related macular degeneration;
neurotrophins for axon regeneration following central nervous system injury; …
| |
Alexandros Sfakianakis
Anapafseos 5 . Agios Nikolaos
Crete.Greece.72100
2841026182
Anapafseos 5 . Agios Nikolaos
Crete.Greece.72100
2841026182
6948891480
No comments:
Post a Comment